Biosimilars in inflammatory bowel disease

被引：2
|
作者：
Moore, Gregory T. [1 ,2 ]
机构：
[1] Monash Hlth, Clayton, Vic, Australia
[2] Monash Univ, Clayton, Vic, Australia
来源：
MEDICAL JOURNAL OF AUSTRALIA | 2016年 / 205卷 / 07期
关键词：
D O I：
10.5694/mja16.00775
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：294 / 295
页数：2
相关论文
共 50 条
  • [21] Insights on the use of biosimilars in the treatment of inflammatory bowel disease
    Michael K Zheng
    David Q Shih
    Gary C Chen
    World Journal of Gastroenterology, 2017, (11) : 1932 - 1943
  • [22] Updates on the Use of Biosimilars for the Treatment of Inflammatory Bowel Disease
    Velayos, Fernando
    PRACTICAL GASTROENTEROLOGY, 2022, 46 (07)
  • [23] Biosimilars in inflammatory bowel disease: ready for prime time?
    Gomollon, Fernando
    CURRENT OPINION IN GASTROENTEROLOGY, 2015, 31 (04) : 290 - 295
  • [24] Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
    Ali Hakizimana
    Iftikhar Ahmed
    Rachel Russell
    Mark Wright
    Nadeem A Afzal
    World Journal of Gastroenterology, 2017, (25) : 4473 - 4479
  • [25] Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
    Hakizimana, Ali
    Ahmed, Iftikhar
    Russell, Rachel
    Wright, Mark
    Afzal, Nadeem A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (25) : 4473 - 4479
  • [26] Comment to "Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease"
    Barreiro de Acosta, Manuel
    Katsanos, Konstantinos H.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (11) : 1302 - 1303
  • [27] The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease
    David Pineles
    Lisa Malter
    Peter S. Liang
    Amy Arsuaga
    Brian Bosworth
    David P. Hudesman
    Shannon Chang
    European Journal of Clinical Pharmacology, 2018, 74 : 1361 - 1362
  • [28] Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico
    Mayoral-Zavala, A.
    Esquivel-Aguilar, A.
    del Real-Calzada, C. M.
    Gutierrez-Grobe, Y.
    Ramos-Garcia, J.
    Rocha-Ramirez, J. L.
    Rojas-Illanes, M. F.
    Rubio-Martinez, B.
    Sanchez-Chavez, X.
    Yamamoto-Furusho, J. K.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (04): : 414 - 423
  • [29] The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease
    Pineles, David
    Malter, Lisa
    Liang, Peter S.
    Arsuaga, Amy
    Bosworth, Brian
    Hudesman, David P.
    Chang, Shannon
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (10) : 1361 - 1362
  • [30] Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
    Al Sulais, Eman
    AlAmeel, Turki
    BIOLOGICS-TARGETS & THERAPY, 2020, 14 : 1 - 11
12345